[특허]Leak detector for sealed optical devices

Oplink Communications, Inc.

검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
검색연산자

검색도움말
검색연산자	기능	검색시 예
()	우선순위가 가장 높은 연산자	예1) (나노 (기계 \| machine))
공백	두 개의 검색어(식)을 모두 포함하고 있는 문서 검색	예1) (나노 기계) 예2) 나노 장영실
\|	두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색	예1) (줄기세포 \| 면역) 예2) 줄기세포 \| 장영실
!	NOT 이후에 있는 검색어가 포함된 문서는 제외	예1) (황금 !백금) 예2) !image
*	검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색	예) semi*
""	따옴표 내의 구문과 완전히 일치하는 문서만 검색	예) "Transform and Quantization"

과학기술 지식인프라 ScienceON

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

특허 상세정보

MyON담기

내보내기 페이스북 공유 트위터 공유 카카오톡 공유

Leak detector for sealed optical devices

특허상세정보
국가/구분	United States(US) Patent 등록
국제특허분류(IPC7판)	G01N-031/00
미국특허분류(USC)	436/003; 436/001; 436/164; 116/004; 073/040.7; 073/040
출원번호	US-0800399 (2001-03-05)
발명자 / 주소	Li, Jason Zhu, Steven Guoxin
출원인 / 주소	Oplink Communications, Inc.
대리인 / 주소	Fish & Richardson P.C.
인용정보	피인용 횟수 : 0 인용 특허 : 1

초록
▼

대표
청구항
▼

This invention discloses a method for detecting a leak from a sealed optical device. The method includes steps of: A) injecting a target gas with no performance interference to the sealed optical device for leak detection followed by sealing the sealed optical device. B) placing the sealed device in a leak testing chamber and measuring a background level of the target gas in the leak testing chamber. C) heating the sealed device to a gas-expelling temperature for expelling the target gas from the leak in the sealed optical device. And, D) detecting the target gas in a one-part-per million (PPM) range in the leak-detecting chamber for an comparing with the background level of the target gas for determining the leak in the sealed optical device. taining an active agent of topiramate, wherein the core particles have an initial particle size between about 0.100 mm and 2.5 mm; and (b) a taste mask coating, wherein the taste mask coating comprises between about 7% by weight and about 15% by weight of the pharmaceutical composition and wherein the coated particles of the pharmaceutical composition have a final particle size of about 0.100 mm to about 2.5 mm. 2. The method of claim 1, wherein the core particles comprise the active agent of topiramate and at least one excipient. 3. The method of claim 2, wherein the core particles comprise the active agent of topiramate, a binder and a diluent wherein the diluent is sugar spheres. 4. The method of claim 3, wherein the taste mask coating comprises between about 9% by weight and about 13% by weight of the pharmaceutical composition. 5. The method of claim 4, wherein the taste mask coating comprises about 11% by weight of the pharmaceutical composition. 6. The method of claim 5, wherein the core particles have an initial particle size between about 0.5 mm and 1.5 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.5 mm and 1.5 mm. 7. The method of claim 6, wherein the core particles have an initial particle size between about 0.710 mm and 1.18 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.850 mm and 1.18 mm. 8. The method of claim 7, wherein the binder is selected from povidone, HPMC, sodium alginate, panwar gum, acacia gum, gelatin, sugar, molasses, starch, pregelatinized starch, methylcellulose, ethylcellulose or carboxymethylecllulose; and the tase mask coating comprises a taste masking agent and a disintegrant, wherein the taste masking agent is selected from cellulose acetate, methylcellulose, ethylecellulose, a methacrylate or acrylate containing polymer or cellulose acetate butyrate; and the disintegrant is selected from povidone, cellulose, carboxycellulose, croscarmellose sodium, magnesium aluminum silicate, starch, sodium starch glycolate, pregelatinized starch, alginic acid or guar gum. 9. The method of claim 8, wherein the binder is povidone, the taste masking agent is cellulose acetate and the disintegrant is povidone. 10. The method of claim 9, wherein the coated particles of the pharmaceutical composition are encapsulated. 11. A method of treating diabetes in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising about 85 to about 93% by weight core beads, and about 7 to about 15% by weight of a coating; wherein the core beads comprise about 18 to about 21% by weight of topiramate, about 8 to about 11% by weight of povidone, and about 58 to about 61% by weight of sugar spheres; and the coating comprises about 6 to about 9% by weight of cellulose acetate, and about 2 to about 5% by weight of povidone. 12. The method of claim 11, wherein the pharmaceutical composition comprises about 89% by weight of core beads and about 11% by weight coating, wherein the core beads comprise about 19.8% by weight topiramate, about 9.9% by weight povidone, and about 59.3% by weight sugar spheres; and the coating comprises about 7.2% by weight cellulose acetate and about 3.8% by weight povidone. a patient; b) quantitatively measuring the pepsinogen-I from said serum sample using an immunoassay and comparing the value obtained to a cut-off value for pepsinogen-I selected from a range of approximately 20-30 μg/l, which overlaps the lower end of the reference range of approximately 25-120 μg/l; and c) quantitatively measuring the gastrin-17 concentration from said serum sample by immunoassay and comparing the values obtained to a reference range of approximately 2-25 pmol/l for gastrin-17, whereby a pepsinogen-I concentration in said serum sample below the cut-off value in combination with a gastrin-17 above the upper reference limit is indicative of atrophy of the corpus area of the stomach. 2. A method for screening for atrophy of the mucosa of the whole stomach from blood serum, such atrophy correlating with increased risk of gastric cancer, which comprises: a) obtaining a serum sample from a patient, b) quantitatively measuring the pepsinogen-I from said serum sample using an immunoassay and comparing the value obtained to a cut-off value for pepsinogen-I selected from a range of approximately 20-30 μg/l, which overlaps the lower end of the reference range of approximately 25-120 μg/l; and c) quantitatively measuring the gastrin-17 concentration from said serum sample and comparing the value obtained to a reference range of 2-25 pmol/l for gastrin-17, whereby a pepsinogen-I concentration in said serum sample below the pepsinogen-1 cut-off value and a gastrin-17 concentration in said serum sample within the reference range for gastrin-17 is indicative of atrophy of the mucosa of the whole stomach. 3. The method according to claim 1 or 2, further comprising a protein stimulation test that measures serum gastrin-17 concentration after fasting and then after a protein rich standard meal. 4. The method according to claim 1 or 2, wherein said immunoassay is conducted with an enzyme labeled antibody and a chromogenic, fluorescent or luminescent substrate, and absorbance, fluorescence or luminescence is measured. 5. The method according to claim 1 or 2, wherein said pepsinogen-I immunoassay is performed using polyclonal or monoclonal antibodies which specifically bind to said pepsinogen-I. 6. The method according to claim 1 or 2, wherein said gastrin-17 immunoassay is performed using polyclonal or monoclonal antibodies which specifically bind to said gastrin-17. 7. The method according to claim 6, wherein a polyclonal antibody to gastrin-17 is obtained by immunizing an animal with the gastrin fragment 1-13, {Leu15}-gastrin-17 or using a gastrin-17 antigen isolated from the stomach of an animal. 8. The method according to claim 6, wherein said monoclonal antibodies are mouse monoclonal antibodies which specifically bind to {Leu15}-gastrin-17 antigen. 9. The method according to claim 1 or 2, further comprising an immunoassay to detect the presence of Helicobacter pylori antibodies. 10. A method for screening for atrophy of the antrum area of the stomach from blood serum such atrophy correlating with increased risk of gastric cancer, which comprises: a) obtaining a blood serum sample from a patient b) quantitatively measuring the pepsinogen-I concentrations using an immunoassay and comparing the value obtained to a cut-off value for pepsinogen-I selected from the range of approximately 20-30 μg/l, which overlaps the lower end of the reference range of approximately 25-120 g/l; and c) quantitatively measuring the gastrin-17 concentration from said serum sample by immunoassay and comparing it to a cut-off value for gastrin-17 selected from a range of approximately 0.1-2 pmol/l, which is below the reference range of approximately 2-25 pmol/l whereby a pepsinogen I concentration above said cut-off value in combination with a gastrin-17 concentration in said sample below said cut-off value is indicative of atrophy of the antrum area of the stomach. 11. The method according to claim 10

이 특허에 인용된 특허 (1)

Hass Hyman (Stamford CT) Murphy Terrence P. (Hempstead NY). Dry-testing system for detecting leaks in containers. USP1976103987664.

IPC 상위 출원인

내보내기

상세정보
내보내기 구분	파일저장 인쇄 메일전송
구성항목	관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표IPC 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 공고번호, 공고일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표출원인, 출원인국적, 출원인주소, 발명자, 발명자E, 발명자코드, 발명자주소, 발명자 우편번호, 발명자국적, 대표IPC, IPC코드, 요약, 미국특허분류, 대리인주소, 대리인코드, 대리인(한글), 대리인(영문), 국제공개일자, 국제공개번호, 국제출원일자, 국제출원번호, 우선권, 우선권주장일, 우선권국가, 우선권출원번호, 원출원일자, 원출원번호, 지정국, Citing Patents, Cited Patents
저장형식	Text(ASCII format) Excel format PIAS분석(.xls)
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	> 총 건의 자료가 검색되었습니다. > 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) > 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. > 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) > 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오 > ~ > Text(ASCII format) Excel format

과학기술 지식인프라 ScienceON

ScienceON Chatbot

연합인증

특허 상세정보

Leak detector for sealed optical devices

초록
▼

대표
청구항
▼

이 특허에 인용된 특허 (1)

IPC 상위 출원인

과제정보

상세정보조회

원문조회

IPC 상세정보(version : 201201)

연구과제 성과물(0)

참여연구원의 다른 문헌(0)

처리중입니다.

잠시만 기다려주세요.

ScienceON Chatbot

연합인증

특허 상세정보

Leak detector for sealed optical devices

초록 ▼

대표청구항 ▼

이 특허에 인용된 특허 (1)

IPC 상위 출원인

과제정보

상세정보조회

원문조회

IPC 상세정보(version : 201201)

연구과제 성과물(0)

참여연구원의 다른 문헌(0)

처리중입니다.

잠시만 기다려주세요.

초록
▼

대표
청구항
▼